Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ADA | P00813 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691945 | 1.00 | BCHE (0.50) | BCHEADAALDH1A1TP53CYP2C9 | |
| SCHEMBL19389373 | 0.90 | ENPP1 (0.51) | BCHEALDH1A1P2RY11ENPP1POLB | |
| SCHEMBL22990586 | 0.90 | BCHE (0.51) | BCHEADAALDH1A1TP53CYP2C9 | |
| SCHEMBL6915658 | 0.90 | BCHE (0.51) | BCHEADAALDH1A1TP53CYP2C9 | |
| SCHEMBL20225033 | 0.90 | BCHE (0.51) | BCHEADAALDH1A1TP53CYP2C9 | |
| SCHEMBL22352146 | 0.88 | P2RY1 (0.54) | BCHEALDH1A1P2RY11POLBP2RY1 | |
| SCHEMBL20692157 | 0.88 | P2RY1 (0.54) | BCHEALDH1A1P2RY11POLBP2RY1 | |
| SCHEMBL24681039 | 0.88 | BCHE (0.48) | BCHEADAALDH1A1TP53CYP2C9 | |
| SCHEMBL1763090 | 0.87 | POLB (0.55) | ALDH1A1P2RY11ENPP1POLBP2RY1 | |
| SCHEMBL29763100 | 0.87 | POLB (0.55) | ALDH1A1P2RY11ENPP1POLBP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | BCHE 3073/4885ADA 241/4885ALDH1A1 1444/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | BCHE 3073/4885ADA 241/4885ALDH1A1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.